Literature DB >> 15342917

Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase.

Philippe P Roux1, Bryan A Ballif, Rana Anjum, Steven P Gygi, John Blenis.   

Abstract

Tuberous sclerosis complex (TSC) is a genetic disorder caused by mutations in either of the two tumor suppressor genes TSC1 or TSC2, which encode hamartin and tuberin, respectively. Tuberin and hamartin form a complex that inhibits signaling by the mammalian target of rapamycin (mTOR), a critical nutrient sensor and regulator of cell growth and proliferation. Phosphatidylinositol 3-kinase (PI3K) inactivates the tumor suppressor complex and enhances mTOR signaling by means of phosphorylation of tuberin by Akt. Importantly, cellular transformation mediated by phorbol esters and Ras isoforms that poorly activate PI3K promote tumorigenesis in the absence of Akt activation. In this study, we show that phorbol esters and activated Ras also induce the phosphorylation of tuberin and collaborates with the nutrient-sensing pathway to regulate mTOR effectors, such as p70 ribosomal S6 kinase 1 (S6K1). The mitogen-activated protein kinase (MAPK)-activated kinase, p90 ribosomal S6 kinase (RSK) 1, was found to interact with and phosphorylate tuberin at a regulatory site, Ser-1798, located at the evolutionarily conserved C terminus of tuberin. RSK1 phosphorylation of Ser-1798 inhibits the tumor suppressor function of the tuberin/hamartin complex, resulting in increased mTOR signaling to S6K1. Together, our data unveil a regulatory mechanism by which the Ras/MAPK and PI3K pathways converge on the tumor suppressor tuberin to inhibit its function.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15342917      PMCID: PMC518784          DOI: 10.1073/pnas.0405659101

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

Review 1.  ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions.

Authors:  Philippe P Roux; John Blenis
Journal:  Microbiol Mol Biol Rev       Date:  2004-06       Impact factor: 11.056

2.  Phosphorylation of p90 ribosomal S6 kinase (RSK) regulates extracellular signal-regulated kinase docking and RSK activity.

Authors:  Philippe P Roux; Stephanie A Richards; John Blenis
Journal:  Mol Cell Biol       Date:  2003-07       Impact factor: 4.272

3.  TSC2 mediates cellular energy response to control cell growth and survival.

Authors:  Ken Inoki; Tianqing Zhu; Kun-Liang Guan
Journal:  Cell       Date:  2003-11-26       Impact factor: 41.582

4.  Inactivation of the tuberous sclerosis complex-1 and -2 gene products occurs by phosphoinositide 3-kinase/Akt-dependent and -independent phosphorylation of tuberin.

Authors:  Andrew R Tee; Rana Anjum; John Blenis
Journal:  J Biol Chem       Date:  2003-07-16       Impact factor: 5.157

Review 5.  United at last: the tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase/Akt pathway to mammalian target of rapamycin (mTOR) signalling.

Authors:  B D Manning; L C Cantley
Journal:  Biochem Soc Trans       Date:  2003-06       Impact factor: 5.407

6.  Phosphorylation of tuberin as a novel mechanism for somatic inactivation of the tuberous sclerosis complex proteins in brain lesions.

Authors:  Sangyeul Han; Túlio M Santos; Ana Puga; Jenn Roy; Elizabeth A Thiele; Mia McCollin; Anat Stemmer-Rachamimov; Vijaya Ramesh
Journal:  Cancer Res       Date:  2004-02-01       Impact factor: 12.701

Review 7.  Rheb fills a GAP between TSC and TOR.

Authors:  Brendan D Manning; Lewis C Cantley
Journal:  Trends Biochem Sci       Date:  2003-11       Impact factor: 13.807

Review 8.  Rhebbing up mTOR: new insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosis.

Authors:  David J Kwiatkowski
Journal:  Cancer Biol Ther       Date:  2003 Sep-Oct       Impact factor: 4.742

Review 9.  Targeting RAS signalling pathways in cancer therapy.

Authors:  Julian Downward
Journal:  Nat Rev Cancer       Date:  2003-01       Impact factor: 60.716

10.  Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb.

Authors:  Andrew R Tee; Brendan D Manning; Philippe P Roux; Lewis C Cantley; John Blenis
Journal:  Curr Biol       Date:  2003-08-05       Impact factor: 10.834

View more
  324 in total

1.  Escherichia coli succinic thiolinase. Stoichiometry of phosphorylation and coenzyme A binding.

Authors:  C M Bowman; J S Nishimura
Journal:  J Biol Chem       Date:  1975-07-25       Impact factor: 5.157

Review 2.  mTOR signaling in growth control and disease.

Authors:  Mathieu Laplante; David M Sabatini
Journal:  Cell       Date:  2012-04-13       Impact factor: 41.582

3.  TGF-β-induced activation of mTOR complex 2 drives epithelial-mesenchymal transition and cell invasion.

Authors:  Samy Lamouille; Erin Connolly; James W Smyth; Rosemary J Akhurst; Rik Derynck
Journal:  J Cell Sci       Date:  2012-03-07       Impact factor: 5.285

4.  ERK1/2 phosphorylate Raptor to promote Ras-dependent activation of mTOR complex 1 (mTORC1).

Authors:  Audrey Carriere; Yves Romeo; Hugo A Acosta-Jaquez; Julie Moreau; Eric Bonneil; Pierre Thibault; Diane C Fingar; Philippe P Roux
Journal:  J Biol Chem       Date:  2010-11-11       Impact factor: 5.157

Review 5.  Rapamycin-resistant effector T-cell therapy.

Authors:  Daniel H Fowler
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

6.  The role of the Birt-Hogg-Dubé protein in mTOR activation and renal tumorigenesis.

Authors:  T R Hartman; E Nicolas; A Klein-Szanto; T Al-Saleem; T P Cash; M C Simon; E P Henske
Journal:  Oncogene       Date:  2009-02-23       Impact factor: 9.867

Review 7.  AKT/PKB Signaling: Navigating the Network.

Authors:  Brendan D Manning; Alex Toker
Journal:  Cell       Date:  2017-04-20       Impact factor: 41.582

8.  The folliculin tumor suppressor is a GAP for the RagC/D GTPases that signal amino acid levels to mTORC1.

Authors:  Liron Bar-Peled; Lynne Chantranupong; Zhi-Yang Tsun; Roberto Zoncu; Tim Wang; Choah Kim; Eric Spooner; David M Sabatini
Journal:  Mol Cell       Date:  2013-10-03       Impact factor: 17.970

9.  Emerging role of mTOR in the response to cancer therapeutics.

Authors:  Erika Ilagan; Brendan D Manning
Journal:  Trends Cancer       Date:  2016-05

10.  Activation of protein synthesis in cardiomyocytes by the hypertrophic agent phenylephrine requires the activation of ERK and involves phosphorylation of tuberous sclerosis complex 2 (TSC2).

Authors:  Mark Rolfe; Laura E McLeod; Phillip F Pratt; Christopher G Proud
Journal:  Biochem J       Date:  2005-06-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.